Palghar-based pharma formulations manufacturer exporting generics to 52 countries, diversifying into pet care, nutraceuticals and mobility.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 228 | +90.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 14.0 | 0.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 13.0 | +85.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 20.48 | +1.6 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -9.76 | −4.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | Trailing twelve months | TTM to Jun 2026 | Not in the analysed materials. No older figure is substituted. |
Guidance
1 of 4 judged targets kept · 18 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Finance Cost | Decline over the next 2 to 3 quarters | Q3 FY26 | Management confirmed that interest costs are 'slowly reducing' due to improved cash flows and a credit rating upgrade to BBB+, fulfilling the promise made in Q3 FY26. | Achieved |
| Fredun Gx Revenue | INR 85 crores this year (FY26) | Q1 FY26 | Promise related to FY26 performance, which was missed. No new update. | Missed |
| Total Revenue | Double revenue to INR 800+ crores in next 3-4 years | Q1 FY26 | Management now expects to cross INR 800 cr in FY27, significantly accelerating the original 3-4 year timeline. | Revised Up |
3 of Fredun Pharmaceuticals Limited's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹1,677.85 on 24 Oct 2025 → ₹1,450.9. High ₹2,814.3 (30 Jun 2026), low ₹885.75 (22 Jul 2026).
Overview
Based on the company's own presentations, annual report and earnings calls.
Fredun Pharmaceuticals manufactures pharmaceutical formulations at its Palghar (Maharashtra) facility, selling branded and export generics such as anti-diabetics, anti-infectives and cardiac ranges to leading Indian pharma companies and to customers across Africa, South-East Asia, CIS, Latin America and the MENA region. It also runs newer 'new-age' consumer-facing divisions - Freossi (pet healthcare and diagnostics), Fredun Nutrition (nutraceuticals), Bird n Beauty/BeautyFred (cosmeceuticals) and Fredun Mobility/Chuu Balm (orthopaedic support and pain-relief products) - largely leveraging its existing pharma distribution network. The company also does contract manufacturing for third parties at facilities beyond its own plant.
Segments
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
1 of 4 judged targets kept · 18 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Finance Cost | Decline over the next 2 to 3 quarters | Q3 FY26 | Management confirmed that interest costs are 'slowly reducing' due to improved cash flows and a credit rating upgrade to BBB+, fulfilling the promise made in Q3 FY26. | Achieved |
| Fredun Gx Revenue | INR 85 crores this year (FY26) | Q1 FY26 | Promise related to FY26 performance, which was missed. No new update. | Missed |
| Total Revenue | Double revenue to INR 800+ crores in next 3-4 years | Q1 FY26 | Management now expects to cross INR 800 cr in FY27, significantly accelerating the original 3-4 year timeline. | Revised Up |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 22 tracked commitments, with each call’s wording and source.
Call summaries
Fredun Pharma Q1 FY27
Fredun Pharma delivered a strong Q1 FY27, with significant top-line and bottom-line growth driven by new age brands and strategic capacity expansion. The company is actively developing its pet care ecosystem, Wagr.in, and projects robust growth across its business segments for the coming years. While confident in its trajectory, management provided cautious guidance on specific high-end targets and margin expansion timelines.
Read the full callFredun Pharma Q4 FY26
Fredun Pharmaceuticals reported a strong Q4 and full FY26, driven by robust revenue growth and significant margin expansion across its businesses. The company saw impressive performance in its new age segments like Pet Care and Mobility, alongside the successful launch of new hormonal and anti-aging product lines. While raw material costs increased due to geopolitical factors, management indicated effective mitigation strategies, and cash flows improved despite ongoing working capital needs.
Read the full callFredun Pharma Q3 FY26
Fredun Pharma delivered strong financial performance in Q3 and 9M FY26, with significant year-on-year growth in revenue, EBITDA, and net profit. The company is rapidly expanding production capacities and seeing strong traction from new brands. Management reiterated its conservative guidance approach and outlined plans for continued growth in both legacy and new-age businesses, with a focus on asset-light manufacturing for newer segments.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 2 fiscal years held (Mar 2025 to Mar 2026).
Financials
Net profit, year on year: +86% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 103 | 167 | 120 | 145 | 161 | 213 | 228 |
| Expenses | 0 | 89 | 150 | 103 | 123 | 135 | 184 | 196 |
| Operating profit | 0 | 13 | 17 | 17 | 22 | 26 | 29 | 33 |
| Operating margin | 13.0% | 13.0% | 10.0% | 14.0% | 15.0% | 16.0% | 14.0% | 14.0% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 5 | 8 | 7 | 8 | 11 | 14 | 9 |
| Depreciation | 0 | 1 | 2 | 1 | 2 | 2 | 3 | 4 |
| Profit before tax | 0 | 7 | 7 | 9 | 13 | 14 | 11 | 21 |
| Tax rate | 44.0% | 25.0% | 17.0% | 25.0% | 26.0% | 25.0% | 4.0% | 36.0% |
| Net profit | 0 | 5 | 6 | 7 | 9 | 10 | 11 | 13 |
| EPS (₹ per share) | 0 | 3.75 | 4.23 | 4.77 | 6.64 | 6.51 | 6.57 | 7.96 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 277 | 349 | 349 | 639 |
| Expenses | 247 | 309 | 307 | 545 |
| Operating profit | 30 | 40 | 40 | 94 |
| Other income | 0 | 0 | 0 | 0 |
| Interest | 10 | 14 | 17 | 40 |
| Depreciation | 3 | 4 | 4 | 8 |
| Profit before tax | 19 | 22 | 20 | 47 |
| Net profit | 11 | 15 | 15 | 37 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 4 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 64 | 92 | 117 | 137 | 153 | 273 |
| Borrowings | 53 | 87 | 106 | 167 | 171 | 222 |
| Other liabilities | 66 | 74 | 81 | 179 | 136 | 142 |
| Total liabilities | 187 | 257 | 308 | 487 | 464 | 642 |
| Fixed assets | 32 | 39 | 47 | 53 | 65 | 118 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 1 | 2 | 2 | 2 |
| Other assets | 155 | 218 | 260 | 433 | 397 | 522 |
| Total assets | 187 | 257 | 308 | 487 | 464 | 642 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 0 | -2 | -14 | 0 | -17 | 12 |
| Cash from investing | -1 | -4 | -9 | -8 | -6 | -74 |
| Cash from financing | -1 | 7 | 25 | 6 | 27 | 121 |
| Net cash flow | -2 | 1 | 1 | -2 | 4 | 60 |
| Free cash flow | -1 | -7 | -24 | -8 | -23 | -62 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 112 | 148 | 46 | 68 | 142 | 53 |
| Inventory days | 242 | 96 | 264 | 246 | 267 | 219 |
| Days payable | 215 | 101 | 104 | 88 | 161 | 71 |
| Cash conversion cycle | 139 | 144 | 205 | 225 | 248 | 201 |
| Working capital days | 116 | 126 | 97 | 92 | 76 | 78 |
| Return on capital employed | 10.0% | 13.0% | 18.0% | 17.0% | — | 21.0% |
| Dividend payout | 14.0% | 5.0% | 3.0% | 2.0% | 2.0% | 1.0% |
To justify its price of ₹1451, this stock must grow earnings at 9% every year for 7 years. Our analysis caps realistic growth at ~49%. At that growth it is worth ₹10652 — upside of 634%.
Ownership
Public hold 52.25% as of Sept 2026; institutions added 0.12 pts since Jul 2026.
since Jul 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 2 holders trimming and 3 off the list — both are in the register beside this.
Named in the Sep 2026 filing
Every holder of Fredun Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Jul 2026.
| Holder | Stake | Change |
|---|---|---|
| 38.53% | newly disclosed | |
| 5.28% | −0.15 pp | |
| 5.08% | newly disclosed | |
| 1.42% | newly disclosed | |
| 1.42% | newly disclosed | |
| Bank | 1.33% | unchanged |
| 1.31% | +0.07 pp | |
| 1.07% | newly disclosed | |
| 1.01% | −0.44 pp | |
| 0.01% | newly disclosed | |
| — | off the list | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Fredun Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.